AL Amyloidosis and Multiple Myeloma
Intersection of Pathophysiology, Diagnosis, and Treatment
Medical Education Review
See also: [[MGUS_vs_MM_Scoring_MASS-FIX_Interpretation|MGUS vs MM: Scoring Systems & MASS-FIX Interpretation]] for comprehensive risk stratification models, MASS-FIX panel decoding, FLC reference ranges by renal function, and kappa vs lambda patterns in MM vs AL amyloidosis.
Executive Summary
- AL amyloidosis and multiple myeloma arise from clonal plasma cell proliferation with distinct clinical presentations despite shared pathogenic mechanisms (1,2)
- 10-15% of multiple myeloma patients develop AL amyloidosis; conversely, approximately 10% of AL amyloidosis patients meet criteria for symptomatic myeloma at diagnosis (3,4)
- Cardiac staging using NT-proBNP and troponin remains the primary prognostic determinant in AL amyloidosis, unlike myeloma where clonal characteristics drive staging (5,6)
- Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd) represents the new standard of care for newly diagnosed AL amyloidosis with significantly improved hematologic complete response rates (7)
- Renal manifestations differ fundamentally: cast nephropathy predominates in myeloma while glomerular amyloid deposition causing nephrotic syndrome characterizes AL amyloidosis (8,9)
- Treatment intensity must be carefully calibrated as AL amyloidosis patients tolerate less intensive regimens than myeloma patients despite use of similar drug classes (10)
1. Introduction and Overview
AL amyloidosis and multiple myeloma represent two distinct yet intimately related plasma cell neoplasms that share fundamental pathogenic mechanisms while manifesting dramatically different clinical phenotypes. Both disorders arise from clonal proliferation of bone marrow plasma cells producing monoclonal immunoglobulin light chains, yet the clinical consequences and therapeutic approaches diverge significantly based on the biochemical behavior of the secreted light chains (1,2). Understanding the intersection of these two conditions is essential for accurate diagnosis, appropriate risk stratification, and optimal treatment selection.
Multiple myeloma is a hematologic malignancy characterized by clonal plasma cell expansion exceeding 10% of bone marrow cellularity or presence of a biopsy-proven plasmacytoma, accompanied by at least one myeloma-defining event including the CRAB criteria (hypercalcemia, renal insufficiency, anemia, bone lesions) or specific biomarkers of malignancy (3). In contrast, AL amyloidosis is defined by the extracellular deposition of misfolded immunoglobulin light chain fibrils that assume a beta-pleated sheet conformation, forming insoluble aggregates that progressively accumulate in vital organs leading to functional impairment and organ failure (4).
The relationship between these disorders is bidirectional and clinically significant. Epidemiological studies demonstrate that 10-15% of patients with multiple myeloma will develop overt AL amyloidosis during their disease course, with up to 38% having clinically occult amyloid deposits detectable on careful evaluation (3,5). Conversely, approximately 10-18% of patients presenting with AL amyloidosis meet International Myeloma Working Group criteria for concurrent symptomatic multiple myeloma at the time of amyloidosis diagnosis (6). This overlap creates diagnostic and therapeutic challenges that require integrated multidisciplinary management.
Clinical Pearl: The key distinction lies in light chain behavior: in myeloma, light chains cause direct organ toxicity primarily through tubular cast formation, while in AL amyloidosis, light chains misfold into amyloid fibrils causing progressive organ infiltration and dysfunction (4,8).
3. Diagnostic Evaluation and Differentiation
3.1 Laboratory Evaluation
The initial diagnostic workup for both conditions relies heavily on characterization of the monoclonal protein. Serum protein electrophoresis (SPEP) with immunofixation identifies the monoclonal immunoglobulin in most multiple myeloma cases but may be negative in up to 50% of AL amyloidosis patients due to the small clone size and predominance of free light chain-only secretion (11). The serum free light chain (FLC) assay has become essential, detecting abnormal FLC ratios in over 98% of patients with either disorder and providing critical quantitative data for monitoring treatment response.
The difference between involved and uninvolved free light chains (dFLC) serves as both a diagnostic and prognostic marker. In AL amyloidosis, dFLC correlates with disease burden and organ involvement severity, with higher levels associated with increased cardiac involvement and poorer outcomes. The dFLC has been incorporated into the Mayo 2012 staging system for AL amyloidosis, using a threshold of 180 mg/L to define high-risk disease (6,12).
Cardiac biomarkers serve fundamentally different roles in these two diseases. In AL amyloidosis, NT-proBNP and cardiac troponin levels directly reflect cardiac infiltration severity and form the backbone of prognostic staging systems. Elevated biomarkers indicate myocardial involvement regardless of symptoms and mandate cardiac evaluation. In multiple myeloma, cardiac biomarker elevation is uncommon and typically reflects concurrent cardiac disease rather than myeloma-specific pathology (5,6).
3.2 Tissue Diagnosis
Definitive diagnosis of AL amyloidosis requires histological demonstration of amyloid deposits in tissue specimens using Congo red staining, which produces pathognomonic apple-green birefringence under polarized light microscopy. Fat pad aspiration combined with bone marrow biopsy achieves diagnostic sensitivity of approximately 90% and represents the preferred initial approach due to minimal invasiveness (4,11). If these sites are negative in a patient with high clinical suspicion, biopsy of an affected organ (kidney, liver, or endomyocardial) may be necessary.
Amyloid typing is essential to confirm AL versus other amyloid subtypes (ATTR, AA, others). Mass spectrometry-based proteomic analysis of laser-microdissected amyloid deposits represents the gold standard for amyloid typing, with accuracy exceeding 98%. Immunohistochemistry and immunofluorescence remain useful but have higher rates of false-negative and false-positive results, particularly for distinguishing AL from ATTR amyloidosis (4,13).
⚠️ Warning: Failure to properly type amyloid deposits can lead to catastrophic therapeutic errors, as the treatment approaches for AL, ATTR, and AA amyloidosis differ fundamentally. ATTR amyloidosis in particular requires differentiation from AL given the availability of effective targeted therapies (13).
3.3 The κ/λ Free Light Chain Ratio as Primary Diagnostic Instrument: A Nephrologist’s Framework
Note on originality: The clinical decision framework below — explicitly framing the FLC ratio as the primary AL amyloidosis screening tool and the monoclonal protein screen as the primary MGUS/MM screening tool — has not been formally articulated in the literature as a unified decision framework. Individual pieces exist: the IMWG guidelines state that renal failure “does not result in an abnormal [FLC] ratio”; the iStopMM study established eGFR-adjusted FLC reference intervals; Gertz 2024 and Palladini 2020 recommend the combination of FLC + immunofixation for AL screening. But the explicit split between what the ratio tests for versus what the monoclonal screen tests for, and the practical implications for nephrologists managing CKD populations, has not been synthesized into a clinical teaching framework in any single publication. This represents a genuine gap.
3.3.1 Two Different Questions, Two Different Tests
The free light chain assay and the monoclonal protein screen (SPEP/immunofixation/MASS-FIX) are frequently ordered together, and in full diagnostic workups they should be — but they are not interchangeable and they do not answer the same clinical question.
| Clinical Question | Primary Test | Mechanism |
|---|---|---|
| Does this patient have AL amyloidosis? | Serum FLC ratio (+ immunofixation as complement) | AL is caused by a small, often invisible plasma cell clone producing an amyloidogenic free light chain. The M-protein may be <0.010 g/dL — undetectable by any conventional method. The FLC ratio detects clonal light chain excess regardless of whether intact immunoglobulin is present |
| Does this patient have MGUS, MGRS, or MM? | Monoclonal protein screen (SPEP ± MASS-FIX + immunofixation + quantitative immunoglobulins) | These disorders are defined by the presence of an intact immunoglobulin clone. The monoclonal screen detects, identifies, and quantifies that clone. The FLC ratio is an essential add-on for risk stratification but is not the primary detection instrument |
The conceptual distinction: in AL amyloidosis, the free light chain is the pathogen — the amyloidogenic light chain directly deposits in tissue and directly kills cardiomyocytes through oxidative stress pathways before fibrils even form. In MGUS/MM, the free light chain ratio is a surrogate marker of clonality — it tells you the clone is producing excess of one light chain type, but the intact immunoglobulin (or the clone’s total production) is what defines the disease and drives the staging thresholds.
This distinction explains why: - In AL amyloidosis, a patient can have a normal M-protein and catastrophic organ failure — what matters is the ratio and the dFLC - In MGUS, a patient can have an M-protein of 2.5 g/dL with a perfectly normal FLC ratio and low progression risk - In light chain MM, the M-protein on SPEP may be absent while the FLC ratio is markedly abnormal
3.3.2 Why Absolute FLC Levels Fail Nephrologists — and Why the Ratio Does Not
This is the single most clinically important point for any physician managing a CKD population:
The problem with absolute levels: Both κ and λ free light chains are small proteins cleared by the kidney. As GFR falls, both accumulate in serum regardless of clonal disease. By CKD Stage 3b (eGFR 30–44 mL/min), median kappa is ~30 mg/L and median lambda is ~25 mg/L — roughly double the upper limit of normal. By Stage 4–5, medians reach ~48 mg/L and ~35 mg/L. The laboratory will flag both as “H” (high) in essentially every CKD patient. Ignoring the result because “FLC is always high in CKD” is clinically rational but diagnostically dangerous. It is precisely the reflex that allowed Mr. Felton’s lambda AL amyloidosis to go undetected.
Why the ratio survives CKD: The critical biological fact, stated clearly in the IMWG FLC guidelines, is that renal failure increases both kappa and lambda proportionally — it does not preferentially elevate one over the other in a way that mimics clonal excess. A plasma cell clone producing excess lambda tips the ratio far beyond what CKD physiology can explain. The iStopMM study (Blood Cancer J, 2022) quantified this precisely: using standard reference intervals (0.26–1.65), 9% of CKD patients appeared to have an abnormal ratio. Using eGFR-adjusted intervals, that fell to 0.7% — a 13-fold reduction in false positives. Among the 0.7% with truly abnormal ratios, clonal disease was confirmed.
The practical rule: In a CKD patient, look at the ratio corrected for GFR, not the absolute values. An absolute kappa of 95 mg/L in a Stage 4 CKD patient is expected and unremarkable. A kappa/lambda ratio of 8.4 in a Stage 4 CKD patient is not explainable by renal physiology and demands investigation for kappa clonal disease.
iStopMM eGFR-Adjusted FLC Ratio Reference Intervals:
| eGFR (mL/min/1.73m²) | Standard Interval (0.26–1.65) | iStopMM Renal-Adjusted Interval |
|---|---|---|
| ≥60 | 0.26–1.65 | 0.26–1.65 |
| 45–59 | (9% false-positive rate) | 0.46–2.62 |
| 30–44 | (higher false-positive rate) | 0.48–3.38 |
| <30 | (significant over-diagnosis) | 0.54–3.30 |
3.3.3 How the Ratio Behaves Across the Plasma Cell Disease Spectrum
Understanding how the FLC ratio behaves differently in each disease state allows a single test result to inform multiple diagnoses:
MGUS: An abnormal FLC ratio is one of the three Mayo 2005 MGUS risk factors (along with M-protein ≥1.5 g/dL and non-IgG isotype). A patient with MGUS and a normal FLC ratio has a 20-year progression risk of only 5%. An abnormal ratio in MGUS triples that risk. For nephrologists: in CKD patients with a monoclonal protein on MASS-FIX, applying the renal-adjusted FLC interval determines whether the FLC ratio is truly abnormal or physiologically elevated — a clinically meaningful distinction because a falsely abnormal ratio would incorrectly escalate the patient’s MGUS risk category.
LC-MGUS (Light Chain MGUS): Defined by an abnormal FLC ratio + elevated involved chain + urinary monoclonal protein <500 mg/24h in the absence of an intact immunoglobulin M-protein. This entity is the specific MGUS subtype that precedes light chain MM and AL amyloidosis. In CKD patients, LC-MGUS can be entirely missed if the clinician dismisses the elevated FLC as “CKD-related” and never checks the ratio against the renal-adjusted interval. The iStopMM study found the crude prevalence of LC-MGUS in CKD patients was 0.5% — not rare, and clinically significant as the precursor state to AL amyloidosis.
MGRS (Monoclonal Gammopathy of Renal Significance): MGRS is uniquely relevant to nephrology because the kidney biopsy drives the diagnosis. The key challenge: a patient with MGRS may have an M-protein that appears to be MGUS-level by every staging metric — low M-protein, <10% marrow plasma cells, no CRAB features. The FLC ratio in MGRS is almost always abnormal, and the degree of abnormality does not correlate with the severity of renal injury. A ratio of 0.05 (extreme lambda excess) can occur with minimal M-protein and devastating glomerular disease. The ratio in MGRS is most useful as: (1) a clonality signal when immunofixation is weakly positive or equivocal; (2) the monitoring metric — serial FLC ratio and dFLC track clone activity and response to clone-directed therapy even when M-protein is too small to quantify on SPEP. For MGRS specifically, the FLC ratio is often the most sensitive and most serializable disease biomarker available.
AL Amyloidosis: The FLC ratio is the primary diagnostic and staging instrument. In 81.9% of untreated AL amyloidosis patients, the FLC ratio is abnormal — by contrast, SPEP detects an M-spike in only ~50% and urine immunofixation in ~86% (Haematologica, 2008). The combination of serum immunofixation + urine immunofixation + FLC achieves >98% detection sensitivity. The ratio direction (low = lambda excess) is pathognomonic in context: a markedly low ratio (<0.2) with unexplained organ dysfunction should trigger immediate amyloid evaluation regardless of M-protein level, renal function, or absence of nephrotic syndrome. The dFLC (≥ 180 mg/L) is the third variable in the Mayo 2012 AL staging system — but as discussed in Section 3.3.4, it requires caution in CKD.
Clinical Pearl: The Gertz 2024 AL amyloidosis update (Am J Hematol) states: “If immunofixation of serum and urine is negative and the Ig FLC (κ:λ) ratio is normal (0.26–1.65), AL amyloidosis is unlikely.” This establishes the FLC ratio as a gatekeeper for AL evaluation. But in CKD, using the standard 0.26–1.65 interval as this gatekeeper will generate false negatives in patients with mildly elevated lambda (from CKD) whose ratio is technically within standard range but should be below the renal-adjusted lower limit. The gatekeeper must use the renal-adjusted interval.
Frank Multiple Myeloma: In MM, the FLC ratio has three distinct roles depending on the myeloma subtype:
Intact immunoglobulin MM (IgG, IgA, IgM): The ratio is abnormal in most cases (reflecting the clonal light chain excess accompanying the intact immunoglobulin), but it is not the primary staging metric. The M-protein level drives staging (MGUS vs SMM vs MM thresholds; Mayo 2018 “20/2/20” SMM model). The ratio’s main role here is as a SLiM criterion: an involved/uninvolved FLC ratio ≥ 100 (with involved FLC ≥ 100 mg/L) is itself a myeloma-defining event independent of M-protein level or CRAB features.
Light chain-only MM: The SPEP is normal or shows only hypogammaglobulinemia. The ratio is the only serum clonal marker. This is the scenario most dangerous in nephrology: a patient presents with AKI, SPEP shows no M-spike, and the clinician misses cast nephropathy because they did not order FLC. The ratio will be markedly abnormal (often >100 for kappa, <0.01 for lambda), and the absolute involved FLC will be in the hundreds to thousands of mg/L. In CKD with concurrent light chain MM, both the ratio and the absolute levels will be dramatically abnormal — far beyond what any degree of renal retention can explain.
Non-secretory MM (<1% of MM): Neither M-protein nor FLC ratio may be detectable. Bone marrow biopsy with FISH drives diagnosis.
3.3.4 The dFLC in CKD: Use With Caution as a Staging Tool, Not as a Screening Tool
The dFLC (difference between involved and uninvolved free light chains) is the key metric in AL amyloidosis Mayo 2012 staging: dFLC ≥ 180 mg/L is one of three staging variables. It also defines hematologic response thresholds (VGPR = dFLC <40 mg/L; partial response = >50% dFLC reduction).
In CKD, however, both kappa and lambda accumulate from renal retention — so the uninvolved chain is not truly at its “physiologic baseline.” This artificially inflates the dFLC:
Worked example from Mr. Felton’s case (lambda AL amyloidosis, CKD Stage 4): - Lambda (involved): 285 mg/L - Kappa (uninvolved): 53.1 mg/L - dFLC = 231.9 mg/L → above Mayo threshold of 180 mg/L - But: expected median kappa in CKD Stage 4 from renal retention alone is ~48 mg/L; expected median lambda is ~35 mg/L - CKD contribution to lambda: ~35 mg/L of the 285 mg/L is physiologic - True clonal lambda excess: ~250 mg/L — still dramatically above threshold - The direction and magnitude are unambiguously clonal; CKD inflation is modest relative to the absolute clonal signal
The hierarchy in CKD: Use the ratio (renal-adjusted) as the diagnostic anchor. Use the dFLC as a supplementary staging metric with awareness that it is modestly inflated. Use serial dFLC for treatment monitoring, comparing to the patient’s own baseline rather than to the absolute threshold — a 50% reduction in dFLC means the same thing regardless of CKD.
Critical exception: In patients with severe CKD (Stage 4–5, particularly dialysis), the dFLC may be inflated enough to falsely assign a higher Mayo stage. A patient on dialysis with a dFLC of 210 mg/L may actually have a lower true clonal burden than that number suggests. Hematology should be aware of this confound when staging AL amyloidosis patients with advanced CKD.
3.3.5 The Nephrologist as First-Line Screener for AL Amyloidosis
Nephrologists occupy a unique diagnostic position. They see: - CKD patients with unexplained proteinuria in whom the free light chains are routinely checked (and routinely dismissed as “CKD-elevated”) - Nephrotic syndrome patients who get kidney biopsies — and may have AL amyloidosis diagnosed after the fact when Congo red is positive - Patients with cardiorenal syndrome who are being worked up for “HFpEF” in whom the cardiac AL phenotype is the actual diagnosis - MGRS patients with clone-mediated glomerular injury that doesn’t meet MM criteria
The intervention required is simple: add FLC ratio interpretation against the renal-adjusted interval to the routine mental checklist for CKD patients with unexplained organ dysfunction. A lambda-predominant ratio (low) in a CKD patient with unexplained cardiac dysfunction, unexplained proteinuria above what CKD predicts, or unexplained neuropathy should trigger an AL amyloidosis evaluation regardless of M-protein level and regardless of whether nephrotic syndrome is present.
Clinical Pearl — The Two-Question Rule for Plasma Cell Disease in Nephrology: 1. Is the κ/λ ratio abnormal for this patient’s GFR? — Use iStopMM renal-adjusted intervals. If no: FLC elevation is physiologic, pursue monoclonal screen for MGUS/MGRS/MM. If yes: go to question 2. 2. What is the direction and magnitude, and does it match the organ dysfunction? - Very low ratio (lambda excess, typically <0.2) + cardiac/renal/neurologic dysfunction → AL lambda amyloidosis evaluation immediately - Very low ratio (lambda excess) + abnormal M-protein on immunofixation → lambda MGRS or lambda MM - Very high ratio (kappa excess, often >5–10, especially >100) → kappa clonal disease: kappa AL, kappa MM, kappa MGRS - Mildly abnormal ratio within 2× the renal-adjusted boundary + no intact immunoglobulin + no organ dysfunction → LC-MGUS; risk-stratify and monitor
4. Diagnostic Delays: A Critical Problem in AL Amyloidosis
4.1 The Burden of Delayed Diagnosis
AL amyloidosis is characterized by substantial diagnostic delays that directly impact patient outcomes. The median time from symptom onset to diagnosis ranges from 6 to 12 months across multiple studies, with many patients experiencing delays exceeding 2 years (10,27). This delay is particularly devastating in a disease where cardiac involvement progresses rapidly and early treatment is essential for organ preservation.
Factors Contributing to Diagnostic Delay:
| Factor | Impact |
|---|---|
| Nonspecific early symptoms | Fatigue, weight loss, edema attributed to common conditions |
| Low disease awareness | Many physicians encounter <1 case in their career |
| Symptom misattribution | Cardiac symptoms → “heart failure”; renal symptoms → “nephrotic syndrome” |
| Multiple specialist visits | Average 3-4 physicians seen before diagnosis |
| Patient delay | Self-interpretation of symptoms as “aging” or minor issues |
Studies consistently show that patients visit an average of 3-4 different physicians before receiving a correct diagnosis, with initial misdiagnoses including heart failure, nephrotic syndrome, chronic kidney disease, carpal tunnel syndrome, and peripheral neuropathy (10,27).
4.2 Cardiac Amyloidosis Misdiagnosed as Heart Failure
The most consequential diagnostic error is the misattribution of cardiac amyloidosis symptoms to “heart failure with preserved ejection fraction” (HFpEF) or hypertensive heart disease. This error is common because:
Clinical Overlap: - Both present with dyspnea, fatigue, and peripheral edema - Both show elevated NT-proBNP and BNP - Both may demonstrate left ventricular hypertrophy on echocardiogram - Both cause diastolic dysfunction
Key Distinguishing Features Often Missed:
| Feature | HFpEF/Hypertensive HD | Cardiac Amyloidosis |
|---|---|---|
| LV wall thickness | Modest (12-14 mm) | Marked (>14 mm, often >16 mm) |
| ECG voltage | Normal or increased | Low voltage (paradox with thick walls) |
| Apical sparing on strain | Absent | Present (“cherry on top” pattern) |
| Response to standard HF therapy | Typically improves | Often worsens or no response |
| Hypotension with ACEi/ARB | Uncommon | Common (autonomic involvement) |
| Associated features | Hypertension history | Periorbital purpura, macroglossia, carpal tunnel |
Consequences of Misdiagnosis: - Standard heart failure medications (ACE inhibitors, beta-blockers, digoxin) may be harmful in cardiac amyloidosis - Digoxin binds to amyloid fibrils, causing toxicity at “therapeutic” levels - Beta-blockers may worsen cardiac output in a heart dependent on heart rate - Delay allows continued amyloid deposition and irreversible cardiac damage - Patients may progress from Stage II to Stage III/IIIb during diagnostic workup
⚠️ Warning: Any patient with “HFpEF” and unexplained left ventricular hypertrophy, especially with low-voltage ECG, should be evaluated for cardiac amyloidosis. A simple screening with serum free light chains and cardiac biomarkers can identify AL amyloidosis. Tc-99m pyrophosphate scintigraphy can identify ATTR amyloidosis non-invasively (13).
4.3 Renal Amyloidosis Misdiagnosed as Primary Nephrotic Syndrome
Renal AL amyloidosis frequently presents with nephrotic-range proteinuria and is commonly misattributed to primary glomerular diseases, particularly: - Minimal change disease - Membranous nephropathy
- Focal segmental glomerulosclerosis (FSGS) - Diabetic nephropathy
The Diagnostic Trap:
Many patients with renal AL amyloidosis receive empiric immunosuppression for presumed primary glomerular disease before the correct diagnosis is established. This delay is particularly harmful because:
- Steroids alone are inadequate: While dexamethasone is part of AL therapy, prednisone monotherapy (typical for minimal change disease) does not address the plasma cell clone
- Immunosuppressants may be harmful: Cyclophosphamide or rituximab given for presumed membranous nephropathy delays appropriate clone-directed therapy
- Continued light chain production: The amyloidogenic clone continues producing toxic light chains during misguided treatment
- Cardiac involvement may develop: Patients with isolated renal AL at presentation may develop cardiac involvement during diagnostic delay
Red Flags Suggesting AL Amyloidosis Rather Than Primary Glomerular Disease:
| Finding | Suggests AL Amyloidosis |
|---|---|
| Age >50 with new nephrotic syndrome | Higher pretest probability |
| Nephrotic syndrome + unexplained cardiac symptoms | Multi-organ involvement |
| Nephrotic syndrome + carpal tunnel syndrome | Systemic amyloid deposition |
| Nephrotic syndrome + autonomic symptoms | Peripheral/autonomic neuropathy |
| Unexplained hepatomegaly or elevated alkaline phosphatase | Hepatic involvement |
| Periorbital purpura, macroglossia | Pathognomonic for AL |
| Monoclonal protein on SPEP/UPEP/FLC | Clonal plasma cell disorder |
Recommended Approach: All patients over age 50 presenting with unexplained nephrotic syndrome should have: - Serum protein electrophoresis with immunofixation - Urine protein electrophoresis with immunofixation - Serum free light chain assay - NT-proBNP and troponin (screen for occult cardiac involvement)
If any of these are abnormal, fat pad aspiration and bone marrow biopsy with Congo red staining should be performed before initiating immunosuppressive therapy for presumed primary glomerular disease.
4.4 Impact of Diagnostic Delay on Outcomes
The relationship between diagnostic delay and survival is stark:
| Time from Symptoms to Diagnosis | Cardiac Stage at Diagnosis | Median OS |
|---|---|---|
| <6 months | Stage I-II predominant | 48+ months |
| 6-12 months | Stage II-III | 24-36 months |
| >12 months | Stage III-IIIb predominant | 12-18 months |
Each month of diagnostic delay: - Allows continued amyloid deposition - Increases likelihood of cardiac involvement - Reduces probability of organ response to treatment - Increases early mortality risk
A study from the UK National Amyloidosis Centre found that patients diagnosed within 6 months of symptom onset had significantly better survival than those diagnosed later, independent of cardiac stage at diagnosis (27).
Clinical Pearl: The three pillars of improving AL amyloidosis outcomes are: (1) Early recognition before advanced organ damage, (2) Effective anti-plasma cell therapy, and (3) Comprehensive supportive care. Diagnostic delay undermines the first pillar and limits the effectiveness of the other two (10).
4.5 Strategies to Reduce Diagnostic Delay
For Cardiologists: - Consider amyloidosis in any HFpEF patient with LVH and low-voltage ECG - Screen with serum free light chains in unexplained LVH - Use Tc-99m PYP scintigraphy to evaluate for ATTR; if negative with abnormal FLC, suspect AL - Recognize that standard HF therapy failure may indicate infiltrative cardiomyopathy
For Nephrologists: - Screen all nephrotic syndrome patients >50 years with SPEP, UPEP, and FLC - Maintain high suspicion when nephrotic syndrome occurs with cardiac or neurologic symptoms - Consider fat pad aspiration before kidney biopsy if amyloidosis is suspected - Remember that AL amyloidosis can mimic any primary glomerular disease histologically
For Primary Care Providers: - Recognize constellation of fatigue + edema + weight loss + dyspnea as potential amyloidosis - Ask about carpal tunnel syndrome, orthostatic symptoms, early satiety - Screen with NT-proBNP and serum free light chains when suspicion exists - Refer promptly to hematology when monoclonal protein is detected
For Hematologists: - Educate colleagues about amyloidosis recognition - Establish rapid referral pathways for suspected cases - Consider AL amyloidosis in any MGUS patient with unexplained organ dysfunction
5. Cardiac Involvement and Prognostic Staging
Cardiac involvement represents the primary determinant of survival in AL amyloidosis, present in approximately 70-90% of patients at diagnosis and responsible for the majority of mortality (5,6). The Mayo Clinic staging systems have evolved to incorporate cardiac biomarkers as the principal prognostic variables, reflecting the central importance of cardiac disease burden (12).
The original Mayo 2004 staging system used NT-proBNP (threshold 332 pg/mL) and cardiac troponin T (threshold 0.035 mcg/L) to stratify patients into three stages with dramatically different median survivals: - Stage I (both normal): ~26 months - Stage II (one elevated): ~11 months
- Stage III (both elevated): ~4 months
The European modification subsequently identified an ultra-high-risk subgroup (Stage IIIb) characterized by NT-proBNP exceeding 8,500 pg/mL with median survival of only 3-5 months (5,14).
The Mayo 2012 staging system incorporated dFLC (threshold 180 mg/L) as a third variable reflecting clonal disease burden, creating a four-stage model: - Stage I: ~94 months median OS - Stage II: ~40 months median OS - Stage III: ~14 months median OS - Stage IV: ~6 months median OS (6,12)
Cardiac Staging Systems Comparison
| Staging System | Biomarkers Used | Thresholds | Stages |
|---|---|---|---|
| Mayo 2004 | NT-proBNP, TnT | NT-proBNP 332 pg/mL, TnT 0.035 mcg/L | I, II, III |
| European Modified | NT-proBNP, TnT | Add NT-proBNP 8,500 pg/mL cutoff | I, II, IIIa, IIIb |
| Mayo 2012 | NT-proBNP, TnT, dFLC | NT-proBNP 1,800 pg/mL, TnT 0.025 ng/mL, dFLC 180 mg/L | I, II, III, IV |
| BU Staging | BNP, TnI | BNP 81 pg/mL, TnI 0.1 ng/mL, BNP 700 pg/mL | I, II, IIIa, IIIb |
Clinical Pearl: The Mayo staging systems for AL amyloidosis are fundamentally different from the International Staging System (ISS) for multiple myeloma. In myeloma, staging reflects tumor burden (beta-2-microglobulin, albumin, LDH, cytogenetics), while AL amyloidosis staging reflects end-organ damage severity (5,6,12).
6. Renal Manifestations: Distinct Pathology, Different Presentations
The kidney serves as a critical target organ in both AL amyloidosis and multiple myeloma, but the pathological mechanisms and clinical presentations differ fundamentally. Understanding these distinctions is essential for appropriate diagnosis, prognostication, and management of renal complications (8,9).
5.1 Multiple Myeloma: Cast Nephropathy
Cast nephropathy (myeloma kidney) represents the most common renal manifestation of multiple myeloma, present in 40-60% of patients with myeloma-related renal disease. The pathogenesis involves excessive filtration of monoclonal free light chains that reach the distal nephron and bind with Tamm-Horsfall protein (uromodulin) secreted by the thick ascending limb. This interaction forms obstructing intratubular casts that trigger an inflammatory response with giant cell reaction, tubular atrophy, and interstitial fibrosis (8,15).
Clinical Presentation: - Acute kidney injury with rapid progression over days to weeks - Serum free light chains often >500-1,500 mg/L - Predominantly tubular proteinuria (Bence Jones protein) - Low albumin excretion (<10% of total proteinuria) - Urine dipstick trace-positive despite substantial proteinuria
Precipitating Factors: - Volume depletion - Hypercalcemia - Nephrotoxic medications (NSAIDs, contrast agents, ACE inhibitors) - Loop diuretics
Light chain cast nephropathy now constitutes a myeloma-defining event per the IMWG criteria (15).
5.2 AL Amyloidosis: Glomerular Disease
In contrast to the tubulointerstitial pathology of myeloma kidney, AL amyloidosis predominantly affects the glomeruli and renal vasculature. Amyloid fibrils deposit within the mesangium and along glomerular and tubular basement membranes, causing progressive obliteration of the capillary lumen and podocyte injury (8,9).
Clinical Presentation: - Nephrotic syndrome with heavy albuminuria (typically >3.5 g/day) - Hypoalbuminemia and peripheral edema - Relatively preserved GFR initially - Progressive renal insufficiency over months to years
Palladini Renal Staging System: - Based on eGFR (threshold 50 mL/min/1.73m²) and 24-hour proteinuria (threshold 5 g/day) - Identifies three stages with progressively higher dialysis risk - Renal involvement does not independently predict mortality like cardiac involvement (9,16)
Renal Manifestations Comparison
| Feature | Cast Nephropathy (Myeloma) | Renal AL Amyloidosis |
|---|---|---|
| Primary Site | Distal tubules, interstitium | Glomeruli, vessels |
| Presentation | Acute kidney injury | Nephrotic syndrome |
| Proteinuria Type | Bence Jones (free light chains) | Albumin-predominant |
| Urine Dipstick | Trace or negative | 3-4+ positive |
| Serum Albumin | Usually normal | Low (severe hypoalbuminemia) |
| Reversibility | Possible with rapid FLC reduction | Slow with sustained hematologic CR |
| FLC Threshold | >500-1500 mg/L typical | May be low (<500 mg/L) |
⚠️ Warning: Approximately 50% of myeloma patients may have occult amyloid deposits on autopsy, and both pathologies can coexist. Kidney biopsy remains the gold standard for differentiating cast nephropathy from AL amyloidosis and identifying overlap syndromes (8,9).
7. Survival Analysis: Comparative Outcomes
6.1 Multiple Myeloma Survival
Multiple myeloma outcomes have improved dramatically over the past two decades with the introduction of novel agents and refinement of transplant strategies. Understanding survival patterns helps contextualize the relative severity of AL amyloidosis and guides treatment intensity decisions.
Historical Context: - Pre-1990s (alkylator era): Median OS 2-3 years - 1990s-2000s (ASCT introduction): Median OS 4-5 years - 2000s-2010s (novel agents: bortezomib, lenalidomide, thalidomide): Median OS 6-8 years - 2010s-present (immunotherapy era: daratumumab, CAR-T): Median OS 8-10+ years
Current Survival by ISS Stage:
| ISS Stage | Criteria | Median OS (Current Era) | 5-Year OS |
|---|---|---|---|
| Stage I | β2M <3.5, Albumin ≥3.5 | ~82 months | ~70% |
| Stage II | Neither I nor III | ~62 months | ~55% |
| Stage III | β2M ≥5.5 | ~40 months | ~40% |
Revised ISS (R-ISS) Outcomes:
| R-ISS Stage | Additional Criteria | 5-Year OS | 5-Year PFS |
|---|---|---|---|
| Stage I | ISS I + standard-risk cytogenetics + normal LDH | 82% | 55% |
| Stage II | Not I or III | 62% | 36% |
| Stage III | ISS III + high-risk cytogenetics or elevated LDH | 40% | 24% |
High-Risk Cytogenetics Impact: - t(4;14): Reduces median OS by ~30% - del(17p): Reduces median OS by ~40-50% - t(14;16): Associated with poor outcomes - Gain 1q21: Emerging adverse prognostic factor - Multiple high-risk features: Median OS may be <3 years despite modern therapy (20)
6.2 AL Amyloidosis Survival
AL amyloidosis demonstrates a fundamentally different survival pattern characterized by high early mortality related to organ dysfunction followed by a plateau phase for responders.
Historical Outcomes: - Pre-2000 (melphalan/prednisone era): Median OS 12-18 months - 2000-2010 (ASCT and novel agents): Median OS 2-4 years - 2010-2020 (bortezomib-based regimens): Median OS 4-5 years - 2021-present (daratumumab era): Median OS 6+ years projected
Survival by Mayo 2004 Cardiac Stage:
| Cardiac Stage | Criteria | Median OS (Historical) | Median OS (Bortezomib Era) | Median OS (Dara Era) |
|---|---|---|---|---|
| Stage I | Normal NT-proBNP and TnT | 26 months | 90+ months | Not reached |
| Stage II | One elevated | 11 months | 40 months | 70+ months |
| Stage III | Both elevated | 4 months | 14 months | 24-36 months |
| Stage IIIb | NT-proBNP >8,500 | 3 months | 5-7 months | 12-18 months |
Key Survival Determinants in AL Amyloidosis: 1. Cardiac stage at diagnosis (most important) 2. Depth of hematologic response (CR vs VGPR vs PR) 3. Time to hematologic response (faster = better) 4. Organ response achievement 5. Presence of autonomic neuropathy (independent adverse factor)
Mortality Patterns: - Early mortality (0-6 months): 20-30% of patients, primarily cardiac deaths - Intermediate phase (6-24 months): Treatment-related and progressive organ failure - Long-term survivors (>2 years): Generally excellent prognosis if in hematologic CR
6.3 Combined AL Amyloidosis and Multiple Myeloma Survival
Patients with concurrent AL amyloidosis and symptomatic multiple myeloma (meeting IMWG criteria for both) represent approximately 10-18% of the AL population and have distinct survival characteristics (6).
Survival Impact of Combined Disease:
| Patient Group | Median OS | 2-Year OS | 5-Year OS |
|---|---|---|---|
| AL amyloidosis alone (cardiac stage I-II) | 60+ months | 75% | 55% |
| Multiple myeloma alone (standard risk) | 80+ months | 85% | 65% |
| AL + MM combined | 30-40 months | 55% | 35% |
| AL + MM with cardiac stage III | 8-12 months | 25% | 15% |
Factors Contributing to Worse Outcomes in Combined Disease: 1. Higher plasma cell burden limits depth of response 2. More frequent high-risk cytogenetic features 3. Greater organ involvement at presentation 4. Treatment intensity limitations due to organ dysfunction 5. Competing risks of myeloma progression and organ failure
Prognostic Hierarchy in Combined Disease: Cardiac stage remains the dominant prognostic factor even when myeloma is present. A patient with Stage IIIb cardiac involvement has poor prognosis regardless of myeloma burden, while Stage I cardiac disease portends reasonable outcomes even with concurrent myeloma (6,24).
6.4 Impact of Treatment on Survival
AL Amyloidosis Treatment Response and Survival:
| Hematologic Response | Median OS | 5-Year OS |
|---|---|---|
| Complete Response (CR) | Not reached | 70-80% |
| Very Good Partial Response (VGPR) | 80+ months | 55-65% |
| Partial Response (PR) | 40 months | 35-45% |
| No Response | 12 months | 10-15% |
ANDROMEDA Trial Survival Data (D-VCd vs VCd):
| Outcome | D-VCd Arm | VCd Arm | Hazard Ratio |
|---|---|---|---|
| Hematologic CR rate | 59.5% | 19.2% | OR 6.03 |
| 5-Year Overall Survival | 76.1% | 64.7% | HR 0.62 |
| 5-Year MOD-PFS | 72% | 48% | HR 0.44 |
| Cardiac CR rate | 40.7% | 13.7% | - |
| Renal CR rate | 57% | 27% | - |
The survival benefit of D-VCd persisted despite >70% of VCd patients receiving daratumumab-based therapy at progression, emphasizing the importance of upfront intensive therapy (7,19).
Multiple Myeloma Treatment Response and Survival:
| Response Depth | 5-Year PFS | 10-Year OS |
|---|---|---|
| MRD-negative (10⁻⁵) | 70-80% | 75-85% |
| Stringent CR | 50-60% | 60-70% |
| Complete Response | 45-55% | 55-65% |
| VGPR | 35-45% | 45-55% |
| PR | 20-30% | 30-40% |
Survival Curves Comparison:
Survival Probability Over Time
100% |*
| * *
80% | * * * (MM standard risk)
| * * * * * * * * * *
60% | * (AL Stage I-II with CR)
| * * * * * *
40% | * * * (AL Stage III)
| * *
20% | * * (AL Stage IIIb)
| * *
0% |_____________*__*_________________
0 12 24 36 48 60 monthsClinical Pearl: The survival curves for AL amyloidosis and multiple myeloma have fundamentally different shapes. Myeloma shows a relatively linear decline over years, while AL amyloidosis demonstrates high early mortality (25-30% at 6 months) followed by a plateau for responders. Long-term AL survivors often outlive myeloma patients if deep response is achieved (10,17).
8. Mortality Outcomes: Treated vs. Untreated Disease
Understanding the natural history of untreated disease provides essential context for the dramatic benefits of modern therapy and underscores the importance of early diagnosis and treatment initiation.
7.1 AL Amyloidosis: Untreated Natural History
Without treatment, AL amyloidosis is uniformly fatal. Historical data from the pre-treatment era and patients who decline or cannot tolerate therapy demonstrate the devastating natural history of this disease.
Untreated AL Amyloidosis Survival:
| Cardiac Stage | Median Survival (Untreated) | 6-Month Survival | 1-Year Survival |
|---|---|---|---|
| Stage I | 12-18 months | 70% | 50% |
| Stage II | 6-9 months | 45% | 25% |
| Stage III | 3-4 months | 20% | 10% |
| Stage IIIb | 2-3 months | 10% | <5% |
| Overall (all stages) | 6-12 months | 40% | 25% |
Causes of Death in Untreated AL Amyloidosis: - Sudden cardiac death (arrhythmia): 40-50% - Progressive heart failure: 25-30% - Multi-organ failure: 15-20% - Renal failure/dialysis complications: 5-10% - Other (bleeding, infection): 5-10%
Key Points: - Amyloid deposition is continuous and progressive without clone suppression - Organ function does not spontaneously improve - Cardiac involvement dominates mortality regardless of other organ involvement - Quality of life deteriorates rapidly due to heart failure, edema, and constitutional symptoms
7.2 AL Amyloidosis: Treated Outcomes
Modern treatment has transformed AL amyloidosis from a rapidly fatal disease to one with meaningful long-term survival for many patients.
Treated AL Amyloidosis Survival by Era:
| Treatment Era | Regimen | Median OS | 5-Year OS |
|---|---|---|---|
| Pre-2000 | Melphalan/Prednisone | 12-18 months | 15% |
| 2000-2010 | ASCT (eligible pts) | 4-5 years | 40% |
| 2010-2020 | Bortezomib-based (VCd) | 4-5 years | 45% |
| 2021-present | D-VCd (ANDROMEDA) | 6+ years (projected) | 65-70% |
Current Treated Survival by Cardiac Stage (D-VCd Era):
| Cardiac Stage | Median OS (Treated) | 5-Year OS | Benefit vs. Untreated |
|---|---|---|---|
| Stage I | Not reached | 85% | +60% absolute |
| Stage II | 80+ months | 70% | +55% absolute |
| Stage III | 36-48 months | 50% | +40% absolute |
| Stage IIIb | 18-24 months | 30% | +25% absolute |
Survival by Hematologic Response (All Treated Patients):
| Response | Median OS | 5-Year OS | 10-Year OS |
|---|---|---|---|
| Complete Response (CR) | Not reached | 80% | 60% |
| Very Good PR (VGPR) | 8+ years | 65% | 45% |
| Partial Response (PR) | 4 years | 40% | 20% |
| No Response | 12 months | 15% | <5% |
Clinical Pearl: The most critical determinant of treated AL amyloidosis survival is achieving deep hematologic response (CR or VGPR). Patients achieving CR have survival approaching that of age-matched controls in some studies. The ANDROMEDA trial showed that daratumumab addition increases CR rates from 18% to 53%, directly translating to improved survival (7).
7.3 Multiple Myeloma: Untreated Natural History
Multiple myeloma without treatment follows a relentlessly progressive course leading to death from skeletal destruction, renal failure, infection, or hyperviscosity.
Untreated Multiple Myeloma Survival (Historical Data):
| Disease Feature | Median Survival (Untreated) | 1-Year Survival |
|---|---|---|
| All patients | 6-12 months | 40% |
| Low tumor burden | 12-18 months | 55% |
| High tumor burden | 4-6 months | 25% |
| With renal failure | 3-6 months | 20% |
| With hypercalcemia | 2-4 months | 15% |
Causes of Death in Untreated Multiple Myeloma: - Infection (immune dysfunction): 35-45% - Renal failure: 20-25% - Disease progression/tumor burden: 15-20% - Hypercalcemia: 5-10% - Bleeding/hyperviscosity: 5-10%
Key Points: - Myeloma cells proliferate continuously without treatment - Bone destruction is progressive, leading to fractures and hypercalcemia - Immune dysfunction leads to life-threatening infections - Renal failure from cast nephropathy may be partially reversible with treatment but not spontaneously
7.4 Multiple Myeloma: Treated Outcomes
Multiple myeloma treatment has undergone revolutionary improvement over six decades.
Treated Multiple Myeloma Survival by Era:
| Treatment Era | Primary Therapy | Median OS | 10-Year OS |
|---|---|---|---|
| Pre-1960s | None/supportive | 6-12 months | <2% |
| 1960-1990 | Melphalan/Prednisone | 2-3 years | 5% |
| 1990-2005 | ASCT introduction | 4-5 years | 15% |
| 2005-2015 | Bortezomib, Lenalidomide | 6-7 years | 30% |
| 2015-present | Daratumumab, CAR-T | 8-10+ years | 45% |
Current Treated Survival by Risk Category:
| Risk Category | Defining Features | Median OS | 5-Year OS |
|---|---|---|---|
| Standard risk | No high-risk cytogenetics | 10+ years | 75% |
| Intermediate risk | t(4;14) or 1q gain | 6-8 years | 55% |
| High risk | del(17p), t(14;16), t(14;20) | 3-5 years | 40% |
| Ultra-high risk | Multiple high-risk features | 2-3 years | 25% |
Survival by Depth of Response:
| Response | Median PFS | 5-Year OS |
|---|---|---|
| MRD-negative (10⁻⁵) | 7+ years | 85% |
| Complete Response | 4-5 years | 70% |
| VGPR | 3-4 years | 60% |
| Partial Response | 2-3 years | 45% |
7.5 Comparative Summary: Treatment Benefit
| Parameter | AL Amyloidosis | Multiple Myeloma |
|---|---|---|
| UNTREATED | ||
| Median OS | 6-12 months | 6-12 months |
| 5-Year OS | <10% | <10% |
| TREATED (Modern Era) | ||
| Median OS | 5-6 years | 8-10 years |
| 5-Year OS | 55-65% | 65-70% |
| 10-Year OS | 35-40% | 45-50% |
| Absolute Benefit of Treatment | ||
| Median OS gain | +4-5 years | +7-9 years |
| 5-Year OS gain | +50% | +55% |
Critical Differences in Mortality Patterns:
- Early Mortality:
- AL amyloidosis: 20-30% die within 6 months despite treatment (cardiac deaths)
- Multiple myeloma: 5-10% early mortality with treatment
- Survival Curve Shape:
- AL: Steep early decline → plateau for responders → near-normal survival for CR patients
- MM: Gradual linear decline over years → relapse-remission cycles → eventual progression
- “Cure” Potential:
- AL: Functional cure possible with sustained CR (organ recovery, normal life expectancy)
- MM: True cure rare; goal is prolonged disease control
- Cause of Death (Treated Patients):
- AL: Cardiac (60%), even with hematologic response
- MM: Disease progression (50%), infection (25%), secondary malignancies (10%)
⚠️ Warning: Both AL amyloidosis and multiple myeloma are fatal without treatment. The dramatic survival improvements with modern therapy (AL: median 6-12 months → 5-6 years; MM: median 6-12 months → 8-10 years) represent among the greatest therapeutic advances in hematologic malignancy. Early diagnosis and prompt treatment initiation are essential for both diseases (7,10,20).
9. Treatment Approaches: Drug Mechanisms and Rationale
While AL amyloidosis and multiple myeloma share the therapeutic goal of eliminating the pathogenic plasma cell clone, the treatment strategies differ substantially. Understanding the mechanism of each drug helps explain why certain combinations are preferred and how dosing must be modified for organ-impaired patients.
7.1 Proteasome Inhibitors
Bortezomib (Velcade)
Mechanism of Action: Bortezomib is a reversible inhibitor of the 26S proteasome, a large intracellular protein complex responsible for degrading ubiquitinated proteins. Plasma cells are exquisitely dependent on proteasome function due to their high rate of immunoglobulin synthesis, which generates substantial endoplasmic reticulum (ER) stress and requires efficient protein quality control.
Cellular Effects: 1. ER Stress Amplification: Inhibition of proteasome-mediated degradation causes accumulation of misfolded proteins in the ER, triggering the unfolded protein response (UPR) and eventual apoptosis 2. NF-κB Inhibition: Prevents degradation of IκB, the inhibitor of NF-κB, blocking this pro-survival pathway critical for plasma cell survival 3. p53 Stabilization: Prevents degradation of the tumor suppressor p53, promoting apoptosis 4. Cell Cycle Arrest: Causes G2/M arrest through accumulation of cell cycle regulatory proteins
Special Relevance to AL Amyloidosis: Amyloidogenic plasma cells produce structurally abnormal light chains that are particularly prone to misfolding. These cells experience higher baseline ER stress than normal plasma cells, making them more susceptible to proteasome inhibition—a phenomenon called “proteotoxic stress sensitization.” This may explain the rapid and deep responses seen with bortezomib in AL amyloidosis (4,10).
Dosing: - Multiple Myeloma: 1.3 mg/m² SC twice weekly (days 1, 4, 8, 11) or weekly - AL Amyloidosis: 1.3 mg/m² SC weekly (reduced intensity due to neuropathy risk and organ fragility)
Key Toxicities: - Peripheral neuropathy (dose-limiting; subcutaneous route reduces risk) - Thrombocytopenia - Gastrointestinal effects - Orthostatic hypotension (problematic in AL patients with autonomic neuropathy)
Carfilzomib (Kyprolis)
Mechanism of Action: Carfilzomib is an irreversible (covalent) proteasome inhibitor that binds the chymotrypsin-like active site of the 20S proteasome with greater specificity than bortezomib. Its irreversible binding provides more sustained proteasome inhibition.
Advantages Over Bortezomib: - Lower rates of peripheral neuropathy - Activity in bortezomib-refractory disease - More potent proteasome inhibition
Limitations in AL Amyloidosis: - Cardiovascular toxicity (heart failure, hypertension, cardiac arrhythmias) limits use in patients with cardiac involvement - Generally avoided as first-line in AL amyloidosis due to cardiac safety concerns - May have role in relapsed AL without cardiac involvement
Dosing (Myeloma): 20 mg/m² cycle 1, then 27-56 mg/m² subsequent cycles IV twice weekly
Ixazomib (Ninlaro)
Mechanism of Action: Oral reversible proteasome inhibitor with similar mechanism to bortezomib but convenient oral administration.
Role in AL Amyloidosis: - Maintenance therapy option after initial response - Alternative for patients intolerant to injectable proteasome inhibitors - Lower peripheral neuropathy rates than bortezomib
Dosing: 4 mg orally weekly (days 1, 8, 15 of 28-day cycle)
7.2 Anti-CD38 Monoclonal Antibodies
Daratumumab (Darzalex)
Mechanism of Action: Daratumumab is a human IgG1κ monoclonal antibody targeting CD38, a transmembrane glycoprotein highly expressed on plasma cells regardless of malignant transformation.
Multiple Mechanisms of Tumor Cell Killing: 1. Complement-Dependent Cytotoxicity (CDC): Binding triggers classical complement cascade leading to membrane attack complex formation 2. Antibody-Dependent Cellular Cytotoxicity (ADCC): Fc region engages NK cells and macrophages to kill antibody-coated plasma cells 3. Antibody-Dependent Cellular Phagocytosis (ADCP): Macrophages engulf opsonized plasma cells 4. Direct Apoptosis: Cross-linking of CD38 induces programmed cell death 5. Immunomodulatory Effects: Depletes CD38+ regulatory T cells, regulatory B cells, and myeloid-derived suppressor cells, enhancing anti-tumor immunity
Importance in AL Amyloidosis: - CD38 is uniformly expressed on AL plasma cells regardless of clone size - Effective even with low bone marrow plasma cell burden (<10%) - Deep responses (CR rates >50%) achieved when combined with VCd - Rapid onset of action critical for preventing further organ damage - Subcutaneous formulation allows convenient outpatient administration
ANDROMEDA Trial Results: The addition of daratumumab to VCd transformed AL amyloidosis treatment: - Hematologic CR: 53% vs 18% - Cardiac CR: 41% vs 14% - 5-year OS: 76% vs 65%
Dosing in AL Amyloidosis (D-VCd): - Cycles 1-2: 1800 mg SC weekly - Cycles 3-6: 1800 mg SC every 2 weeks - Maintenance: 1800 mg SC every 4 weeks for up to 24 cycles
Key Toxicities: - Infusion/injection site reactions (reduced with SC formulation) - Infections (hypogammaglobulinemia) - Neutropenia - Interference with blood bank testing (anti-CD38 causes panreactive indirect Coombs)
Isatuximab (Sarclisa)
Mechanism of Action: Chimeric IgG1 anti-CD38 monoclonal antibody with similar mechanisms to daratumumab but binds a different CD38 epitope. May have enhanced direct apoptosis induction.
Current Role: - Approved for relapsed myeloma in combination with pomalidomide-dexamethasone or carfilzomib-dexamethasone - Under investigation in AL amyloidosis
7.3 Immunomodulatory Drugs (IMiDs)
Lenalidomide (Revlimid)
Mechanism of Action: Lenalidomide binds cereblon (CRBN), a component of the E3 ubiquitin ligase complex CRL4^CRBN. This binding alters the substrate specificity of the complex, leading to ubiquitination and proteasomal degradation of specific transcription factors.
Key Targets Degraded: 1. Ikaros (IKZF1) and Aiolos (IKZF3): Transcription factors essential for plasma cell survival; their degradation triggers rapid plasma cell apoptosis 2. CK1α (Casein Kinase 1α): Contributes to cytotoxicity in myeloma cells with del(5q)
Additional Effects: - Enhanced NK cell and T cell function (immunomodulation) - Anti-angiogenic effects - Direct anti-proliferative effects - Cytokine modulation (decreased TNF-α, IL-6; increased IL-2)
Role in AL Amyloidosis: - Second-line therapy for bortezomib-refractory disease - Part of maintenance strategies - Requires dose adjustment for renal impairment (significant concern given renal AL) - Caution with cardiac amyloidosis due to fluid retention and BNP elevation
Dosing: - Myeloma: 25 mg daily days 1-21 of 28-day cycle - AL Amyloidosis: 15 mg daily (reduced dose); 10 mg if CrCl 30-50 mL/min; 5 mg if CrCl <30 mL/min
Key Toxicities: - Myelosuppression (neutropenia, thrombocytopenia) - Venous thromboembolism (requires prophylaxis) - Fatigue - Elevated NT-proBNP (may confound cardiac response assessment in AL) - Teratogenicity
Pomalidomide (Pomalyst)
Mechanism of Action: More potent cereblon binder than lenalidomide with similar mechanism but enhanced efficacy in lenalidomide-refractory disease.
Role in AL Amyloidosis: - Relapsed/refractory setting - Does not require renal dose adjustment (advantage over lenalidomide) - Combined with dexamethasone ± daratumumab
Dosing: 4 mg daily days 1-21 of 28-day cycle
7.4 Alkylating Agents
Cyclophosphamide
Mechanism of Action: Cyclophosphamide is a nitrogen mustard alkylating agent that requires hepatic activation to its active metabolites (phosphoramide mustard and acrolein). The active metabolites form DNA crosslinks, preventing DNA replication and transcription.
Cellular Effects: 1. DNA Crosslinking: Inter-strand crosslinks prevent DNA strand separation during replication 2. Cell Cycle Arrest: Triggers G2/M checkpoint activation 3. Apoptosis Induction: Activates intrinsic apoptotic pathway
Role in AL Amyloidosis: - Component of standard VCd and D-VCd regimens - Oral administration allows outpatient therapy - Modest single-agent activity but synergistic with bortezomib - Well-tolerated at doses used in AL amyloidosis
Dosing in D-VCd: - 300 mg/m² orally weekly (maximum 500 mg/week)
Key Toxicities: - Myelosuppression - Nausea/vomiting - Hemorrhagic cystitis (rare at doses used in AL) - Secondary malignancies (with prolonged use)
Melphalan
Mechanism of Action: Nitrogen mustard alkylating agent with similar mechanism to cyclophosphamide but does not require hepatic activation.
High-Dose Melphalan (HDM) for ASCT: - Dose: 140-200 mg/m² (based on cardiac function in AL) - Provides myeloablative conditioning - Allows deep responses through clone eradication
Low-Dose Melphalan: - Historical backbone of AL amyloidosis treatment (with dexamethasone) - Now largely replaced by bortezomib-based regimens - Still used in frail patients unable to tolerate other therapies
Dosing: - ASCT conditioning: 140 mg/m² (cardiac involvement) to 200 mg/m² (no cardiac involvement) - Standard therapy: 0.22 mg/kg days 1-4 every 28 days (MDex regimen)
7.5 Corticosteroids
Dexamethasone
Mechanism of Action: Synthetic glucocorticoid with multiple anti-plasma cell effects:
- Glucocorticoid Receptor Activation: Binds cytoplasmic glucocorticoid receptor, translocates to nucleus, modulates gene transcription
- Pro-Apoptotic Effects: Induces BIM expression and downregulates anti-apoptotic proteins (Bcl-2, Mcl-1)
- NF-κB Inhibition: Suppresses pro-survival signaling
- Cell Cycle Arrest: G1 arrest through p21 induction
- Anti-Inflammatory Effects: Reduces IL-6 and other pro-myeloma cytokines
Role in AL Amyloidosis: - Component of all standard regimens - Provides rapid cytoreduction - Caution required due to fluid retention, hyperglycemia, and immunosuppression
Dosing: - Standard: 40 mg weekly - Reduced: 20 mg weekly (frail patients, elderly, poorly controlled diabetes)
Key Toxicities: - Fluid retention (problematic in cardiac AL) - Hyperglycemia - Insomnia, mood changes - Immunosuppression - Muscle weakness - Osteoporosis
7.6 Summary: Drug Selection Rationale
Why D-VCd is Standard for AL Amyloidosis:
| Drug | Contribution to Regimen |
|---|---|
| Daratumumab | Highest CR rates; active regardless of clone size; rapid response |
| Bortezomib | Exploits proteotoxic vulnerability of amyloidogenic cells; proven efficacy |
| Cyclophosphamide | Synergistic cytotoxicity; oral convenience; well-tolerated |
| Dexamethasone | Rapid cytoreduction; enhances partner drug activity |
Why Myeloma Regimens Differ:
Multiple myeloma regimens incorporate lenalidomide (VRd, DRd, KRd) due to: - Higher plasma cell burden requiring sustained control - Better tolerability in patients without organ dysfunction
- Proven maintenance benefit - MRD-driven treatment goals
Lenalidomide is typically avoided first-line in AL amyloidosis due to: - Fluid retention worsening cardiac status - NT-proBNP elevation confounding response assessment - Renal excretion problematic with renal AL - Less urgent need for maintenance given lower relapse rates with deep response
Clinical Pearl: The most dangerous error in AL amyloidosis treatment is applying myeloma-intensity regimens to patients with significant organ dysfunction. A patient with AL amyloidosis and 15% bone marrow plasma cells should NOT receive myeloma-dose therapy—organ function, not clone size, determines tolerable treatment intensity (10,17).
10. Autologous Stem Cell Transplantation
Autologous stem cell transplantation (ASCT) following high-dose melphalan conditioning represents the most effective treatment for achieving deep, durable responses in both AL amyloidosis and multiple myeloma. However, patient selection criteria and outcomes differ substantially (10,17,21).
ASCT Eligibility Comparison
| Parameter | Multiple Myeloma ASCT | AL Amyloidosis ASCT |
|---|---|---|
| Eligibility Rate | 80-85% of patients <70 years | 15-25% of patients |
| Age Cutoff | Generally <70-75 years | Generally <65-70 years |
| Cardiac Restriction | Minimal (LVEF >40%) | Strict (cardiac stage I-II, NT-proBNP <5,000) |
| Melphalan Dose | 200 mg/m² standard | 140-200 mg/m² (based on cardiac status) |
| TRM Rate | 1-3% | 2-5% (experienced centers) |
| CR Rate Post-ASCT | 30-40% | 40-50% |
AL Amyloidosis ASCT Selection Criteria
Standard Eligibility: - Age ≤65-70 years - ECOG performance status 0-2 - Cardiac stage I or II (NT-proBNP <5,000 pg/mL) - No symptomatic heart failure - No significant orthostatic hypotension - ≤2 major organs involved - Creatinine clearance >30 mL/min (relative)
Melphalan Dose Selection: - 200 mg/m²: No cardiac involvement, excellent performance status - 140 mg/m²: Mild cardiac involvement, borderline eligibility - Intermediate doses based on institutional protocols
11. Response Assessment and Monitoring
9.1 Hematologic Response in AL Amyloidosis
| Response | Criteria |
|---|---|
| Complete Response (CR) | Negative serum and urine immunofixation + normal FLC ratio |
| Very Good Partial Response (VGPR) | dFLC <40 mg/L |
| Partial Response (PR) | >50% reduction in dFLC |
| No Response | Does not meet PR criteria |
9.2 Organ Response in AL Amyloidosis
Cardiac Response: - >30% AND >300 pg/mL decrease in NT-proBNP (if baseline >650 pg/mL), OR - ≥2 NYHA class improvement
Renal Response: - ≥30% reduction in proteinuria or drop to <0.5 g/24h - WITHOUT ≥25% eGFR decline
Hepatic Response: - ≥50% decrease in abnormal alkaline phosphatase, OR - Decrease in liver size by imaging
9.3 Myeloma Response Criteria (IMWG)
| Response | Criteria |
|---|---|
| Stringent CR (sCR) | CR + normal FLC ratio + no clonal cells by IHC/flow |
| Complete Response (CR) | Negative immunofixation + <5% marrow plasma cells |
| VGPR | ≥90% M-protein reduction or immunofixation-only detectable |
| Partial Response (PR) | ≥50% M-protein reduction |
12. Managing Concurrent AL Amyloidosis and Multiple Myeloma
Approximately 10-18% of patients present with concurrent AL amyloidosis and symptomatic multiple myeloma. Management requires integration of strategies for both conditions (6,10).
Guiding Principles: 1. Stage using BOTH AL cardiac staging and myeloma ISS 2. Calibrate treatment intensity to organ function, NOT myeloma risk category 3. Monitor BOTH myeloma parameters (M-protein, MRD) AND AL parameters (dFLC, organ biomarkers) 4. Cardiac stage remains dominant prognostic factor even with concurrent myeloma
⚠️ Warning: AL amyloidosis patients with >10% bone marrow plasma cells are at highest risk of receiving inappropriately intensive myeloma-based regimens. Cardiac function, not marrow involvement, should drive treatment intensity decisions (10,17).
13. Future Directions and Emerging Therapies
Fibril-Targeting Approaches
- Birtamimab: Monoclonal antibody targeting amyloid deposits directly
- Doxycycline: Disrupts amyloid fibril stability
- CAEL-101: Anti-amyloid antibody in clinical trials
Cellular Therapies
- BCMA-targeted CAR-T: Under investigation in AL amyloidosis
- Bispecific T-cell engagers: Teclistamab, other BCMA×CD3 BiTEs
- Cardiac toxicity (cytokine release syndrome) requires careful management
Novel Agents
- Venetoclax: BCL-2 inhibitor; particularly active in t(11;14) disease (common in AL)
- Belantamab mafodotin: BCMA-targeted antibody-drug conjugate
- Selinexor: XPO1 inhibitor
Clinical Pearl: The three pillars for improving AL amyloidosis outcomes remain: (1) early disease recognition before advanced organ damage, (2) effective anti-plasma cell therapy achieving rapid deep hematologic response, and (3) comprehensive supportive care including cardiology, nephrology, and neurology collaboration (10).
References
Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38. PMID: 30361501
Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111-2119. PMID: 28126930
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. PMID: 25439696
Wisniowski B, Wechalekar A. Confirming the diagnosis of amyloidosis. Acta Haematol. 2020;143(4):312-321. PMID: 32074611
Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168(2):186-206. PMID: 25312307
Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31(34):4319-4324. PMID: 24145346
Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46-58. PMID: 34192431
Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report. Nat Rev Nephrol. 2019;15(1):45-59. PMID: 30510265
Nasr SH, Valeri AM, Sethi S, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59(6):786-794. PMID: 22417785
Gertz MA, Dispenzieri A, Muchtar E. Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021;96(6):1546-1577. PMID: 34088411
Dasari S, Theis JD, Vrana JA, et al. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clin Proc. 2020;95(9):1852-1864. PMID: 32861330
Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995. PMID: 22331953
Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412. PMID: 27143678
Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. PMID: 15365071
Leung N, Rajkumar SV. Acute kidney injury in multiple myeloma and light chain cast nephropathy. Blood Cancer J. 2023;13(1):44. PMID: 36977666
Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325-2332. PMID: 25115889
Sanchorawala V. Differences and similarities in treatment paradigms and goals between AL amyloidosis and multiple myeloma. Hemato. 2021;2(4):611-621.
Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71-80. PMID: 32244252
Kastritis E, Sanchorawala V, Merlini G, et al. Final overall survival results from the ANDROMEDA study. Blood. 2024;144(Suppl 1). ASH 2024
Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962. PMID: 27002115
D’Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis. J Clin Oncol. 2015;33(32):3741-3749. PMID: 26416996
Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers. J Clin Oncol. 2012;30(36):4541-4549. PMID: 23091105
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. PMID: 27511158
Bochtler T, Hegenbart U, Heiss C, et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood. 2011;117(14):3809-3815. PMID: 21310922
Edwards CV, Bhutani D, Gerstman E, et al. Addressing the challenges of diagnosis and treatment in AL amyloidosis: an era of therapeutic innovation. JCO Oncol Pract. 2023;19(5):265-274. PMID: 36516355
Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and immune therapy treatment strategies. JACC CardioOncol. 2021;3(4):467-487. PMID: 34729519
Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32(10):920-928. PMID: 26498943
McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11(2):207-216. PMID: 28913778
Document prepared for medical education purposes
Last updated: January 2025